Healthcare | August 03, 2021
Meddo acquires Doxper in a cash and stock deal
This deal makes Meddo, one of the largest health-tech players in India
This deal makes Meddo, one of the largest health-tech players in India
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Takeda Will Focus its Efforts on Dengue, Zika and Pandemic vaccines
The study was conducted in patients with mild to moderate COVID-19
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
This acquisition marks PPS’ foray into the development and manufacturing of peptide APIs
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
